Integron Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.30 Cr
as on 19-06-2024
- Paid Up Capital ₹ 1.26 Cr
as on 19-06-2024
- Company Age 17 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 12.71%
(FY 2020)
- Profit 93.62%
(FY 2020)
- Ebitda 108.31%
(FY 2020)
- Net Worth 19.37%
(FY 2020)
- Total Assets 13.59%
(FY 2020)
About Integron Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.30 Cr and a paid-up capital of Rs 1.26 Cr, as per Ministry of Corporate Affairs (MCA) records.
Saji Chalil, Jaya Narayanan, Jasmin Faizal, and Four other members serve as directors at the Company.
- CIN/LLPIN
U51397KL2007PTC020904
- Company No.
020904
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jun 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Thrissur, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Integron Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prasad Sivadas  | Managing Director | 07-Jan-2011 | Current |
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Saji Chalil | Director | 07-Jan-2011 | Current |
| Jaya Narayanan | Director | 07-Jan-2011 | Current |
| Jasmin Faizal | Director | 07-Jan-2011 | Current |
| Karuvarath Shanoj | Director | 07-Jan-2011 | Current |
| Kizhakkapedika Varghese | Director | 07-Jan-2011 | Current |
| Thaniyan Salim | Whole-Time Director | 08-Jun-2007 | Current |
Financial Performance and Corporate Structure Insights of Integron Pharma.
Integron Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 12.71% increase. The company also saw a substantial improvement in profitability, with a 93.62% increase in profit. The company's net worth Soared by an impressive increase of 19.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Integron Pharma?
In 2020, Integron Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
13 years 7 months Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Integron Pharma?
Integron Pharma has a workforce of 39 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Nov 09, 2010, Integron Pharma has raised a total of ₹ 5.9 M, with the most recent deal valued at ₹ 0.7 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
